Hot Investor Mandate 1: China VC Fund Invests in Pharma/Biotech, Devices and Healthcare IT

A China-based healthcare investment firm has launched a new US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Family Venture Fund Seeks Healthcare IT Solutions and Healthcare Services

A venture capital firm backed by a single LP looks to make growth-stage investments in the form of preferred equity, ranging from $1M-$5M initially, with additional capital reserved for follow-on financings, typically up to $10M over the life of the investment. The firm usually leads rounds, but is also open to syndicating with other investors. The firm looks to do 2-4 deals a year, and invests in U.S. and Canadian companies. Prospective companies may have some business overseas as long as they are headquartered in the U.S. or Canada.

The firm makes about one-half of its investments in healthcare, and is open to any healthcare companies that do not require FDA approval for their product/service. However, the firm focuses on B2B-oriented healthcare services and healthcare IT solutions. Some of the firm’s recent healthcare investments include a mobile telemedicine triage service company that provides mobile diabetic retinopathy eye exams as well as an EMR system to help orthopedic surgeons increase productivity.

The firm typically looks for growing companies with a run rate of $1M or a signed contract that would put them at a $1M run rate. The firm has no strict requirements in terms of management team, and will work with first-time entrepreneurs. The firm looks to take a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: PE Firm Seeks Shipping Medtech Products That Reduce the Cost of Healthcare

A private equity firm based in London, UK with an exclusive focus on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is sub-sector and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Health Investment Firm Looks Opportunistically for Biotech and Medtech Innovation

An investment firm based in China is focused on medical and health industry investments. The fund is currently investing from its RMB 687 million (USD 100 million) fund. Typical allocation ranges from USD 2 -20 million in companies from Angel, Series A to Pre-IPO rounds. The firm has invested in 12 companies – 5 in medical devices, 6 in biotech and pharma, and 1 in online education. The firm is seeking opportunities from across the world with a focus on China, USA, and Israel.

The firm is opportunistic across sectors including biotechnology and pharmaceutical, medical devices, mobile medical technologies and medical services. The fund is stage agnostic.

The firm is looking for experienced teams with passion and competence, who can deliver innovative, advanced, and market-oriented technology with huge business potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Is the Early Stage Opportunistic Investment Strategy Broken?

By Dennis Ford, Founder & CEO, LSN

In the last decade there has been an enormous shift in the drug discovery and development landscape. None of the following diatribe will be news to the life science mavens who get this…but I do want to set up for the thesis at the end of the article. Whereas R&D was previously limited mainly to a handful of pharmaceutical companies, new R&D paradigms have evolved that embrace collaborative partnerships amongst various stakeholders in the life science sectors: pharma, biotech, academic/research centers, government, and donor-backed foundations.

Lower productivity, as measured by the number of technology assets that make it to the patient coupled with increasing drug development costs, as well as higher attrition rates at all phases of the discovery and development process, have forced pharmaceutical companies to significantly pare down their internal R&D infrastructures and to increasingly focus on drug development, particularly post proof-of-concept. Thus, early-stage drug discovery is increasingly occurring outside of pharma for all but the ‘big’ diseases. This is the major change that has been driving the biotech investment environment. As the reader probably knows LSN’s arena is matching up buyers and sellers in early stage drugs, devices, diagnostics and healthcare IT.

VC funding for early-stage drug research in the biotech space has become limited because of the high risk and extended timing to exit. This has resulted in disease-focused healthcare foundations frequently left to play a leading role in driving the earliest phases of drug discovery and development—particularly for rare diseases and less prevalent indications. While disease-focused foundations collectively put billions of dollars into life science research, these groups are often dependent on donors and face yearly uncertainty over funds. In addition, their non-profit status limits their ability to take an equity stake in any technology, where a financial gain could then be used to reinvest into the foundations mission. It’s therefore difficult for most disease-focused foundations to implement an investment model that will lead to a tangible impact. Overall this dynamic has impeded the delivery of cures that could address the unmet need that exists for many diseases.

My own observation from living in the space has been that a lot of players that could make early stage investments are reluctant to make early-stage investments. The few that are willing to do so, will generally invest only if something potentially breakthrough or disruptive appears on the radar screen. However, what typically happens is that they will place a large bet on advancing a single opportunity or platform only to move down a dead-end path, at which point they just say ‘never mind’. I would argue that that this places a lot of capital at unnecessary risk. There is a better strategy for making early stage investments. I have come to the conclusion that, yes, the opportunity is there in early stage; but I would want to place my bet on funding multiple early stage technologies rather than just one. For example, it would be a mistake to bet heavily on one small molecule program and leave out the promises of gene therapy, therapeutic proteins, cell therapy etc. especially where there is an unmet medical need and no cure or treatment which is the case with many rare diseases. I think the near future will hold an opportunity for those diseases with no cure in sight by discovering and combining diverse technology assets to help move the needle.

Tips on How to Improve Your RESI Innovation Challenge Application – And Your Investor Pitch

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

The LSN Innovation Challenge is a competition held at every RESI Conference that provides early-stage companies with a unique opportunity to showcase their technologies at a meeting typically attended by 400 – 500 investors. LSN invites thirty top-tier early-stage fundraising companies to pitch their technologies in a poster format at a venue that provides ready access to a range of investors. The RESI Innovation Challenge has become an exciting event at each RESI meeting that attracts a lot of attention from entrepreneurs and investors alike.

The LSN scientific review team spends a lot of time reviewing applications, that now number in the hundreds, prior to selecting the top thirty. As the Innovation Challenge application deadline draws near (November 18th, folks!), we thought we would share with you how we select the winners. LSN’s scientific review team has compiled some tips on how to submit a compelling Innovation Challenge application.

Keep in mind that, while the following is focused on the Innovation Challenge application itself, the criteria and the tips we provide are also relevant for the fundraising process. Many of the questions we ask are similar to what investors will ask when you are out fundraising.

How do you achieve a high score on your application?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system. Companies are stack-ranked on their scores and we invite the top 30 to present at RESI. Our evaluation process is based not only on scientific merit, but also on how ready the company is to present to an investor (“investor-readiness”). A high scoring company might have a transformational technology that can address a high unmet need using a novel approach or target. In addition to innovation, differentiation, unmet need, and market fit, investors are keenly interested in a broad IP position, an experienced management team and CEO with top-tier advisors, and strategic alliances with manufacturing and clinical partners (if the company is at that stage). LSN also looks at whether the company has “investor-ready” marketing material (executive summary, pitch deck, website).

Application Tips

Clearly describe your technology.

Like any marketing material, you need to be clear. Be sure to understand and answer the questions fully. Instead of saying “my company has a proprietary treatment for many critical illnesses”, it would be much clearer to say, “we are developing an IND-ready small molecule asset for breast cancer by activating natural killer cells.”

Lack of clarity will diminish your chances to participate in the Innovation Challenge.

Be realistic with your answers.

The team frequently reviews applications that don’t adequately highlight the competition. Novel products typically do have competitor’s products that precede them. The key point is to highlight how your technology differentiates itself from competitors.

For example, competitors for your disease-modifying therapeutic may only treat disease symptoms. You should identify existing therapeutics and highlight how your technology may offer a disease-modifying alternative.

Explain your current company status in detail.

Outline your current status, as well as provide your view of the strategic direction of your company. When describing your management team, avoid ambiguous statements such as, “CEO is an experienced entrepreneur”. Instead, provide details that highlight the CEO’s experience – years as an entrepreneur, number and names of companies exited, background expertise, etc.

Summarize near-term and long-term strategy.

If you do not have certain criteria, such as a strategic alliance or IP, it’s OK. State your current standing and provide what steps you are currently taking to reach that milestone.

For Alliances and Collaborations, summarize key relationships – focus on KOLs, medical centers, big pharma, and clinical and manufacturing partners. If there is no signed agreement, stating any verbal relationships would be helpful. If you don’t have issued patents yet, state how many patent applications you have filed or are planning to file. Providing us your strategy is better than a simple yes or no.

Provide enough information but don’t go over-board.

Spend more than 5 minutes on this application, but don’t spend 5 hours. Your answers should be brief, but reasonably detailed. We have received hastily done applications that lacked key information—which quickly received a low score and didn’t make the cut. The questions are all straight-forward that you should be comfortable in answering and have down pat. Remember, your executive summary should include answers to many of these questions already.

Send us your marketing material.

If you have marketing material, send it. We do read it and it can help your score. This includes your pitch deck, executive summary, website, videos – any supplemental material that can boost our understanding of your technology and whether your company is investor-ready. The application provides limited space. While this forces you to get straight to the point, supplemental material explains what an application sometimes doesn’t allow (i.e. figures, graphs, pipeline, non-confidential data, etc.)

Overall, applying for the Innovation Challenge is great practice for fundraising companies. For those who have yet to apply, be sure to take note of these suggestions and apply here before November 18th!

237521341025992000

resi-san-francisco-2017

RESI San Francisco Panel Announcement: Corporate VCs & Strategic Investment

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem.  Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.

At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.

The panelists are:

In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.

If you’d like to be there in person, you can register for RESI now.

resi-san-francisco-2017